

Pharmaceutical Manufacturer Perspectives

John Kovalski, Ph.D.

GPhA Perspective

Teva Pharmaceuticals USA

An overview of the impact of the USP residual solvents requirements from the perspective of a generic drug manufacturer will be given. While the goal of all pharmaceutical manufacturers is the development of safe and effective products, this presentation will provide suggestions and recommendations to implement this requirement in a practical risk based manner. Some key discussion points will also be presented.